Literature DB >> 12733875

Charge optimization increases the potency and selectivity of a chorismate mutase inhibitor.

Ajay Mandal1, Donald Hilvert.   

Abstract

The highest affinity inhibitor for chorismate mutases, a conformationally constrained oxabicyclic dicarboxylate transition state analogue, was modified as suggested by computational charge optimization methods. As predicted, replacement of the C10 carboxylate in this molecule with a nitro group yields an even more potent inhibitor of a chorismate mutase from Bacillus subtilis (BsCM), but the magnitude of the improvement (roughly 3-fold, corresponding to a DeltaDeltaG of -0.7 kcal/mol) is substantially lower than the gain of 2-3 kcal/mol binding free energy anticipated for the reduced desolvation penalty upon binding. Experiments with a truncated version of the enzyme show that the flexible C terminus, which was only partially resolved in the crystal structure and hence omitted from the calculations, provides favorable interactions with the C10 group that partially compensate for its desolvation. Although truncation diminishes the affinity of the enzyme for both inhibitors, the nitro derivative binds 1.7 kcal/mol more tightly than the dicarboxylate, in reasonable agreement with the calculations. Significantly, substitution of the C10 carboxylate with a nitro group also enhances the selectivity of inhibition of BsCM relative to a chorismate mutase from Escherichia coli (EcCM), which has a completely different fold and binding pocket, by 10-fold. These results experimentally verify the utility of charge optimization methods for improving interactions between proteins and low-molecular weight ligands.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12733875     DOI: 10.1021/ja029447t

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  8 in total

1.  Absolute binding free energy calculations: on the accuracy of computational scoring of protein-ligand interactions.

Authors:  Nidhi Singh; Arieh Warshel
Journal:  Proteins       Date:  2010-05-15

2.  Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism.

Authors:  Kathleen M Meneely; Qianyi Luo; Andrew P Riley; Byron Taylor; Anuradha Roy; Ross L Stein; Thomas E Prisinzano; Audrey L Lamb
Journal:  Bioorg Med Chem       Date:  2014-09-16       Impact factor: 3.641

3.  Evolving the naturally compromised chorismate mutase from Mycobacterium tuberculosis to top performance.

Authors:  Jūratė Fahrig-Kamarauskaitė; Kathrin Würth-Roderer; Helen V Thorbjørnsrud; Susanne Mailand; Ute Krengel; Peter Kast
Journal:  J Biol Chem       Date:  2020-10-09       Impact factor: 5.157

4.  A "Reverse-Schur" Approach to Optimization With Linear PDE Constraints: Application to Biomolecule Analysis and Design.

Authors:  Jaydeep P Bardhan; Michael D Altman; B Tidor; Jacob K White
Journal:  J Chem Theory Comput       Date:  2009       Impact factor: 6.006

5.  Charge Optimization Theory for Induced-Fit Ligands.

Authors:  Yang Shen; Michael K Gilson; Bruce Tidor
Journal:  J Chem Theory Comput       Date:  2012-06-17       Impact factor: 6.006

Review 6.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

7.  Preliminary X-ray crystallographic analysis of the secreted chorismate mutase from Mycobacterium tuberculosis: a tricky crystallization problem solved.

Authors:  Ute Krengel; Raja Dey; Severin Sasso; Mats Okvist; Chandra Ramakrishnan; Peter Kast
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-04-12

8.  Evolving the naturally compromised chorismate mutase from Mycobacterium tuberculosis to top performance.

Authors:  Jūrate Fahrig-Kamarauskait; Kathrin Würth-Roderer; Helen V Thorbjørnsrud; Susanne Mailand; Ute Krengel; Peter Kast
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.